130 related articles for article (PubMed ID: 14733866)
41. The Changing Clinical Spectrum of Human Immunodeficiency Virus (HIV)-Related Oral Lesions in 1,000 Consecutive Patients: A 12-Year Study in a Referral Center in Mexico.
Ramírez-Amador V; Esquivel-Pedraza L; Sierra-Madero J; Anaya-Saavedra G; González-Ramírez I; Ponce-de-León S
Medicine (Baltimore); 2003 Jan; 82(1):39-50. PubMed ID: 12544709
[TBL] [Abstract][Full Text] [Related]
42. [HIV/AIDS patients in a Critical Care Unit: The experience of a general hospital in a developing country].
Verdugo F; Pinto F; Charpentier P; Von Mühlenbrock C; Soto A; Dabanch J; Fica A
Rev Chilena Infectol; 2015 Jun; 32(3):294-303. PubMed ID: 26230436
[TBL] [Abstract][Full Text] [Related]
43. Rate of candidiasis among HIV-infected children in Spain in the era of highly active antiretroviral therapy (1997-2008).
Álvaro-Meca A; Jensen J; Micheloud D; Díaz A; Gurbindo D; Resino S
BMC Infect Dis; 2013 Mar; 13():115. PubMed ID: 23510319
[TBL] [Abstract][Full Text] [Related]
44. Malignancies in HIV: pre- and post-highly active antiretroviral therapy.
Nutankalva L; Wutoh AK; McNeil J; Frederick WR; Reddy RB; Daftary M; Gentles A; Addae-Afoakwa K
J Natl Med Assoc; 2008 Jul; 100(7):817-20. PubMed ID: 18672558
[TBL] [Abstract][Full Text] [Related]
45. Decrease in Epstein-Barr virus-positive AIDS-related lymphoma in the era of highly active antiretroviral therapy.
Hishima T; Oyaizu N; Fujii T; Tachikawa N; Ajisawa A; Negishi M; Nakamura T; Iwamoto A; Hayashi Y; Matsubara D; Sasao Y; Kimura S; Kikuchi Y; Teruya K; Yasuoka A; Oka S; Saito K; Mori S; Funata N; Sata T; Katano H
Microbes Infect; 2006 Apr; 8(5):1301-7. PubMed ID: 16697236
[TBL] [Abstract][Full Text] [Related]
46. Short- and long-term outcome of HIV-infected patients admitted to the intensive care unit.
van Lelyveld SF; Wind CM; Mudrikova T; van Leeuwen HJ; de Lange DW; Hoepelman AI
Eur J Clin Microbiol Infect Dis; 2011 Sep; 30(9):1085-93. PubMed ID: 21331480
[TBL] [Abstract][Full Text] [Related]
47. Lung cancer in HIV positive patients: the GICAT experience.
Bearz A; Vaccher E; Martellotta F; Spina M; Talamini R; Lleshi A; Cacopardo B; Nunnari G; Berretta M; Tirelli U;
Eur Rev Med Pharmacol Sci; 2014; 18(4):500-8. PubMed ID: 24610616
[TBL] [Abstract][Full Text] [Related]
48. Incidence of opportunistic and other infections in HIV-infected children in the HAART era.
Gona P; Van Dyke RB; Williams PL; Dankner WM; Chernoff MC; Nachman SA; Seage GR
JAMA; 2006 Jul; 296(3):292-300. PubMed ID: 16849662
[TBL] [Abstract][Full Text] [Related]
49. Mortality and morbidity of HIV infected patients receiving HAART: a cohort study.
Panos G; Samonis G; Alexiou VG; Kavarnou GA; Charatsis G; Falagas ME
Curr HIV Res; 2008 May; 6(3):257-60. PubMed ID: 18473789
[TBL] [Abstract][Full Text] [Related]
50. Profile analysis of patients with HIV/AIDS hospitalized after the introduction of antiretroviral therapy.
Nunes AA; Caliani LS; Nunes MS; da Silva AS; de Mello LM
Cien Saude Colet; 2015 Oct; 20(10):3191-8. PubMed ID: 26465860
[TBL] [Abstract][Full Text] [Related]
51. Mucocutaneous manifestations of HIV-infected patients in the era of HAART in Guangxi Zhuang Autonomous Region, China.
Han J; Lun WH; Meng ZH; Huang K; Mao Y; Zhu W; Lian S
J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):376-82. PubMed ID: 22212015
[TBL] [Abstract][Full Text] [Related]
52. Overview of cancer incidence and mortality among people living with HIV/AIDS in British Columbia, Canada: Implications for HAART use and NADM development.
Chiu CG; Smith D; Salters KA; Zhang W; Kanters S; Milan D; Montaner JSG; Coldman A; Hogg RS; Wiseman SM
BMC Cancer; 2017 Apr; 17(1):270. PubMed ID: 28410587
[TBL] [Abstract][Full Text] [Related]
53. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.
Bonnet F; Lewden C; May T; Heripret L; Jougla E; Bevilacqua S; Costagliola D; Salmon D; Chêne G; Morlat P
Cancer; 2004 Jul; 101(2):317-24. PubMed ID: 15241829
[TBL] [Abstract][Full Text] [Related]
54. Admissions to intensive care unit of HIV-infected patients in the era of highly active antiretroviral therapy: etiology and prognostic factors.
Chiang HH; Hung CC; Lee CM; Chen HY; Chen MY; Sheng WH; Hsieh SM; Sun HY; Ho CC; Yu CJ
Crit Care; 2011 Aug; 15(4):R202. PubMed ID: 21871086
[TBL] [Abstract][Full Text] [Related]
55. Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy.
Salzberger B; Hartmann P; Hanses F; Uyanik B; Cornely OA; Wöhrmann A; Fätkenheuer G
Infection; 2005 Oct; 33(5-6):345-9. PubMed ID: 16258865
[TBL] [Abstract][Full Text] [Related]
56. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
Pozio E
Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
[TBL] [Abstract][Full Text] [Related]
57. Morbidity and mortality in HIV-infected children on antiretroviral therapy in Togo.
Mouhari-Touré A; Mahamadou G; Kombate K; Akakpo AS; Teclessou JN; Singo A; Pitché P
Med Sante Trop; 2018 Feb; 28(1):54-60. PubMed ID: 29616646
[TBL] [Abstract][Full Text] [Related]
58. Cancer incidence and all-cause mortality in HIV-positive patients in Northeastern Algeria before and during the era of highly active antiretroviral therapy.
Chaabna K; Newton R; Vanhems P; Laouar M; Forman D; Boudiaf Z; Soerjomataram I
J Cancer Res Ther; 2016; 12(2):576-81. PubMed ID: 27461613
[TBL] [Abstract][Full Text] [Related]
59. Effect of highly active antiretroviral therapy on hospitalization characteristics of HIV-infected patients.
Nuesch R; Geigy N; Schaedler E; Battegay M
Eur J Clin Microbiol Infect Dis; 2002 Sep; 21(9):684-7. PubMed ID: 12373504
[TBL] [Abstract][Full Text] [Related]
60. Mortality and progression to AIDS after starting highly active antiretroviral therapy.
van Sighem AI; van de Wiel MA; Ghani AC; Jambroes M; Reiss P; Gyssens IC; Brinkman K; Lange JM; de Wolf F;
AIDS; 2003 Oct; 17(15):2227-36. PubMed ID: 14523280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
